ESHAP Salvage Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma.
10.3346/jkms.2002.17.5.621
- Author:
Chul Won CHOI
1
;
Chang Won PAEK
;
Jae Hong SEO
;
Byung Soo KIM
;
Sang Won SHIN
;
Yeul Hong KIM
;
Jun Suk KIM
Author Information
1. Division of Hemato-Oncology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea. kjs6651@kumc.or.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Lymphoma;
Non-Hodgkin;
Salvage Therapy;
Recurrence
- MeSH:
Adolescent;
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects;
Bone Marrow/drug effects;
Cisplatin/*administration & dosage/adverse effects;
Cytarabine/*administration & dosage/adverse effects;
Disease-Free Survival;
Drug Tolerance;
Etoposide/*administration & dosage/adverse effects;
Female;
Humans;
Lymphoma, Non-Hodgkin/*drug therapy;
Male;
Methylprednisolone/*administration & dosage/adverse effects;
Middle Aged;
Recurrence;
Retrospective Studies;
Salvage Therapy
- From:Journal of Korean Medical Science
2002;17(5):621-624
- CountryRepublic of Korea
- Language:English
-
Abstract:
The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma (NHL) in therapeutic trials. We undertook this study to determine whether this regimen would be effective and tolerable in Korean patients. A total of 40 patients with refractory or relapsed NHL (8 indolent and 32 aggressive) were enrolled in this study. The overall response rate was 70% (95% confidence interval; 59.8-89.7%); 22.5% of patients achieved a complete response and 47.5% a partial response. The median survival duration was 12 months (95% confidence interval; 5.9-18.1 months) and the median duration of progression-free survival was 9 months (95% confidence interval; 1.1-16.9 months). The median survival duration of patients with relapsed NHL was longer than that of patients with refractory lymphoma (15 months vs 4 months, p=0.02). Myelosuppression was the most frequent complication and treatment-related mortality was noted in two patients. These results suggest that the ESHAP regimen is effective in patients with relapsed NHL who have a sensitive disease. The role of ESHAP chemotherapy in discriminating patients who are more likely to benefit from a subsequent transplant should be evaluated in the future.
